02:39 PM EDT, 10/07/2024 (MT Newswires) -- Oscar Health ( OSCR ) has revenue growth goals, but with limited short-term visibility, and margin and earnings estimates are expected to be below targets, UBS said in a note Monday.

The company is executing growth initiatives cautiously, projecting a revenue of $11.1 billion in 2025, and a more conservative stance for 2026 and 2027 due to the expiration of enhanced subsidies, the investment firm said.

Oscar Health ( OSCR ) projects a decline in membership, but aims to offset that through 8% growth in existing markets and 10% expansion into new markets by 2026, UBS noted.

The company has successfully reduced general and administrative costs per member to $100 from $170, signaling improved cost control measures, according to UBS.

UBS set a neutral rating and $23 price target for Oscar Health ( OSCR ).

Price: 18.43, Change: -1.71, Percent Change: -8.49